<DOC>
	<DOCNO>NCT01025596</DOCNO>
	<brief_summary>This study evaluate safety new experimental drug , IL-7 , people HCV infection resistant 12 week bi-therapy .</brief_summary>
	<brief_title>Dose Escalation Study IL-7 Bi-therapy HCV Patients Resistant After 12 Weeks Bi-therapy ( ECLIPSE 1 )</brief_title>
	<detailed_description>This Phase I inter-patient dose-escalation study assess weekly dos Interleukin-7 ( CYT107 ) adult patient infect Genotype 1 Virus Hepatitis C resistant standard treatment Peg-Interferon Ribavirin ( biotherapy ) 12 week standard bi-therapy . The dose escalation aim establish safety biologically active dos CYT107 add combination therapy pegylated interferon-alpha ribavirin . At dose level , study patient receive subcutaneous administration CYT107 per week total 4 administration . Groups 3 6 patient enter dose level CYT107 . Four dose level plan . Eligible patient cycle four weekly injection define dose level addition bi-therapy . Standard bi-therapy continue 4 week CYT107 treatment discontinuation . The duration study approximately 11 week include screening period . Participants 1 hospitalization overnight 8 clinic visit . The four administration sub-cutaneous give shot skin arm abdomen leg . During study visit follow may do : - Medical history , physical examination , blood test every visit . - Electrocardiogram ( EKG ) - Chest x-ray study - Liver/spleen image - Blood sample collection frequent interval - Urine test several time study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Main Genotype I infect patient Age &gt; 18 year Absence early viral response first treatment PEGinterferonalpha plus ribavirin give least 12 week . Absence early viral response ( EVR ) define detectable HCV decrease HCV RNA load &lt; 2 log , measure quantitative PCR test , compare baseline level measure similar technique Ongoing treatment PEGinterferonalpha plus ribavirin study entry Main Infection HBV Infection HIV1 /or HIV2 Apart HCV infection , presence active infection require specific treatment hospitalization Cirrhosis ( Metavir F4 ) assess biopsy FibroScan® liver biopsy within last 6 month prior CYT107 treatment initiation . If assess Fibroscan® patient result &gt; 10 KPa exclude Other liver disease ( notably alcoholic , metabolic immunological origin ) Body mass index ( BMI ) &gt; 30kg/m2 Inability give inform consent Administration growth factor ( GCSF , EPO ) within 12 week combination therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune-based therapy</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>chronic hepatitis</keyword>
	<keyword>resistance Peg-interferon ribavirin bi-therapy</keyword>
	<keyword>immune specific response HCV</keyword>
	<keyword>phase 1</keyword>
	<keyword>viral disease</keyword>
	<keyword>liver disease</keyword>
</DOC>